D-1566-2020 Class II Terminated
FDA drug recall D-1566-2020 was initiated by Teva Pharmaceuticals USA on Aug 24, 2020 and is designated Class II. Reason for recall: Sub-Potent Drug: Out of specification test results for potency (below specification). The recall status is terminated (terminated Dec 16, 2021). Affected quantity: 38,487 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 16, 2020
- Initiation Date
- Aug 24, 2020
- Termination Date
- Dec 16, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 38,487 bottles
Product description
Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, 100 mL bottle when mixed, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-4177-73.
Reason for recall
Sub-Potent Drug: Out of specification test results for potency (below specification).
Distribution pattern
Nationwide in the U.S. and Puerto Rico.
Code information
Lot #: 30310638A, Exp. 02/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1566-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026